ImproveR International (BI-001-IM)

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting. In particular, data will be collected to analyze experiences of bivalirudin use in respect to the following objectives;

• examine the aspects of safety and effectiveness of bivalirudin

• gain experience regarding the characteristics of patients in bivalirudin treatment

• evaluate the handling of bivalirudin and its practicality

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nycomed
• Treatments: Bivalirudin

Criteria

Inclusion Criteria:

> 18 years, undergoing planned or urgent PCI with the intention to use bivalirudin as anticoagulant, written informed concent to entry of data information registry.

Exclusion Criteria:

None